Skip to main content
Evidence Snapshot

RAW264.7

CHEMBL612557 CELL-LINE Mus musculus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:09:38Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL612557
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats RAW264.7 as ChEMBL target CHEMBL612557. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
RAW264.7
CELL-LINE · Mus musculus
As of 2026-09-13
ChEMBL target ID
CHEMBL612557
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why RAW264.7 matters

As of 2026-09-13

RAW264.7 is reviewed as RAW264.7; the current evidence base includes 34 approved drugs, 14020 compounds, and 5616 assays, with lead potency reaching pChEMBL 11.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 34 approved drugs, 14020 compounds, and 5616 assays for this target. The dominant activity type is IC50. CHEMBL5072364 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL5072364 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
34 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why RAW264.7 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

14020
Total Compounds
5616
Total Assays
34
Approved Drugs
IC50: 9093.0, EC50: 194.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5072364
 11.0 IC50 —
No preferred name
CHEMBL5089388
 10.9 IC50 —
No preferred name
CHEMBL3329998
 10.8 IC50 —
No preferred name
CHEMBL5075905
 10.8 IC50 —
No preferred name
CHEMBL5083589
 10.7 IC50 —

Approved Drugs

Structure Compound First Approval
PEXIDARTINIB
CHEMBL3813873
 2019
BELINOSTAT
CHEMBL408513
 2014
FLUTICASONE FUROATE
CHEMBL1676
 2007
VORINOSTAT
CHEMBL98
 2006
CELECOXIB
CHEMBL118
 1998
ALENDRONATE SODIUM
CHEMBL675
 1995
BUDESONIDE
CHEMBL1370
 1994
ETOPOSIDE
CHEMBL44657
 1983
IBUPROFEN
CHEMBL521
 1974
DOXORUBICIN
CHEMBL53463
 1974
INDOMETHACIN
CHEMBL6
 1965
DEXAMETHASONE
CHEMBL384467
 1958
HYDROCORTISONE
CHEMBL389621
 1952
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:09:38Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL612557